Omaveloxolone drug-drug interaction study with omeprazole in healthy volunteers

Phase 1, open-label trial of omaveloxolone (2 arms), sponsored by Biogen. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration of Omeprazole at Day 17 and Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity of Omeprazole at Day 17. Started Sep 2025; status: completed.